Recruiting

Phase 1

MM-310A Study Evaluating MM-310 in Patients With Solid Tumors

Sponsor:

Merrimack Pharmaceuticals

Code:

NCT03076372

Conditions

Solid Tumors

Urothelial Carcinoma

Gastric Carcinoma

Squamous Cell Carcinoma of the Head and Neck

Ovarian Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MM-310

Study Details

Brief summary:

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.

Conditions

Solid Tumors

Urothelial Carcinoma

Gastric Carcinoma

Squamous Cell Carcinoma of the Head and Neck

Ovarian Cancer

Study ID

NCT03076372

Start date

Feb 22, 2017

Status verified date

Feb, 2018

Completion date

Dec, 2018

Anticipated

Primary completion date

Jun, 2018

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Must have one of the following cancers, for which the patient has either received or been intolerant to all therapy known to confer clinical benefit

Urothelial carcinoma
Gastric/gastroesophageal junction/esophageal carcinoma (G/GEJ/E)
Squamous Cell Carcinoma of the Head and neck (SCCHN)
Ovarian cancer
Pancreatic ductal adenocarcinoma (PDAC)
Prostate adenocarcinoma (PAC)
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Triple negative breast cancer (TNBC)
Endometrial carcinoma
Soft tissue sarcoma subtypes except GIST, desmoid tumors and pleomorphic rhabdomyosarcoma
Able to provide informed consent, or have a legal representative able and willing to do so
≥ 18 years of age
Availability of a cancerous lesion amenable to biopsy and willing to undergo a pre-treatment biopsy
ECOG Performance Status of 0 or 1
Adequate bone marrow reserve as evidenced by:

ANC > 1,500/µl (unsupported by growth factors) and
Platelet count > 100,000/µl
Hemoglobin > 9 g/dL
Patients must have adequate coagulation function as evidenced by prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) within normal institutional limits
Adequate hepatic function as evidenced by:

Serum total bilirubin ≤ ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN.
Alkaline phosphatase ≤ 2.5 x ULN, unless the elevated alkaline phosphatase is due to bone metastasis.
In case alkaline phosphatase is >2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 x ULN
Adequate renal function as evidenced by a serum/plasma creatinine < 1.5 x ULN
Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopecia
Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 6 months following the last dose of MM-310.

Exclusion Criteria:

Prior treatment with docetaxel within 6 months of study enrollment
Pregnant or lactating
Treatment with systemic anticoagulation (e.g. warfarin, heparin, low molecular weight heparin, anti-Xa inhibitors, etc.) except aspirin
Any evidence of hematemesis, melena, hematochezia, ≥ grade 2 hemoptysis, or gross hematuria
Any history of hereditary bleeding disorders
Presence of an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled
Known CNS metastases
Known hypersensitivity to the components of MM-310, or docetaxel
Prior treatment with MM-310
Received treatment, within 28 days or 5 half-lives, whichever is shorter, prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state and all prior clinically significant treatment related toxicities have resolved to Grade 1 or baseline
Received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days (or have not yet recovered from any actual toxicities of the most recent therapy) prior to the first scheduled dose of MM-310
Received any anti-cancer drug known to have anti-VEGF/VEGFR activity within a period of 5 half-lives of this drug (e.g. 100 days for bevacizumab, 75 days for ramucirumab) prior to the first scheduled dose of MM-310
Clinically significant cardiac disease, including: NYHA Class III or IV congestive heart failure, unstable angina, acute myocardial infarction within six months of planned first dose, arrhythmia requiring therapy (including torsades de pointes, with the exception of extrasystoles, minor conduction abnormalities, or controlled and well treated chronic atrial fibrillation)
Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator
Patients who received organ or allogeneic bone marrow or peripheral blood stem cell transplants
Chronic use of corticosteroids more than 10mg daily prednisone equivalent during the past 4 weeks prior to planned start of MM-310
Concomitant use of strong inhibitors of CYP3A
Patients with peripheral neuropathy of grade 2 or higher

Study Design

Enrollment

34 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: MM-310 monotherapy

MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.

Interventions

MM-310

Primary outcome measure

Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors. [ Time Frame: 18 months ]

Central Contacts and Locations

Central contacts

Vasileios Askoxylakis, MD, PhD

617.441.7492 VAskoxylakis@merrimack.com

Locations

Honor Health

Recruiting

Scottsdale, Arizona, United States, 85259

University California San Francisco

Recruiting

San Francisco, California, United States, 94143

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55902

Roswell Park Cancer Institute

Recruiting

Buffalo, New York, United States, 14263

Duke University

Recruiting

Durham, North Carolina, United States, 27710

More Information

Sponsor

Merrimack Pharmaceuticals

Last update posted

Feb 27, 2018

Last verified

Feb, 2018

Keywords

Cancer
Oncology
Phase I
Gemcitabine
Carboplatin
MM-310
EphA2
Ephrin A2
Solid tumors
urothelial carcinoma
gastric carcinoma
squamous cell carcinoma of the head and neck
ovarian cancer
pancreatic ductal adenocarcinoma
prostate adenocarcinoma
non-small cell lung cancer
small cell lung cancer
triple negative breast cancer
endometrial carcinoma
soft tissue sarcoma
Merrimack

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Merrimack Pharmaceuticals on 2018-02-27.